Comparative Pharmacology
Head-to-head clinical analysis: BREYNA versus LESSINA 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREYNA versus LESSINA 28.
BREYNA vs LESSINA-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BREYNA is a contraceptive vaginal ring that releases ethinyl estradiol and etonogestrel. Etonogestrel is a progestogen that inhibits ovulation by suppressing gonadotropin release. Ethinyl estradiol enhances the contraceptive effect by stabilizing the endometrium and increasing cervical mucus viscosity.
Combination of a progestin (levonorgestrel) and an estrogen (ethinyl estradiol). Inhibits ovulation by suppressing gonadotropin release; increases cervical mucus viscosity to impede sperm penetration, and induces endometrial changes that reduce implantation likelihood.
1 mg subcutaneously twice daily
One tablet (0.1 mg levonorgestrel and 0.02 mg ethinyl estradiol) orally once daily for 28 days, starting on the first day of menstrual cycle.
None Documented
None Documented
Terminal elimination half-life is 12 hours; in patients with moderate to severe renal impairment, half-life may be prolonged up to 24 hours, requiring dose adjustment
Terminal elimination half-life: 18-22 hours; clinically relevant for once-daily dosing.
Primarily renal excretion of unchanged drug (approximately 70%) and biliary/fecal elimination (approximately 30%)
Renal: 30% as unchanged drug and metabolites; biliary/fecal: 70% as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive